Jenburkt Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹26.5cr−5.0% on FY25
Free cash flow: ₹26.5cr−5.0% on FY25
Cash from financing: −₹8.9cr−₹7.6 cr in FY25
Cash from investing: −₹19.5cr−₹17.0 cr in FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	3.1	2.7	2.3	2.3
	−4.8	−0.3	−0.2	1.6
	−1.0	−1.1	−3.7	−1.6
	−0.1	1.9	0.2	−1.0
Cash from operating activities
	50.5	43.9	35.2	32.9
	26.5	27.9	8.1	17.1
Cash from investing activities
	0.0	—	0.0	0.0
	39.1	37.6	26.8	16.7
	0.2	0.1	0.1	0.0
	−19.5	−17.0	−0.6	2.6
Cash from financing activities
	0.6	0.6	0.5	0.5
	−8.9	−7.6	−7.1	−21.0
	−1.8	3.2	0.5	−1.4
Reference items
	40.2	37.2	30.5	27.7
	23.8%	24.5%	21.5%	20.3%
	26.5	27.9	8.1	17.1
	0.76×	0.87×	0.31×	0.69×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JENBURPH₹875.95

Jenburkt Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	2.3	2.3	2.7	3.1
Changes in Working Capital
+ Inventories	1.6	-0.2	-0.3	-4.8
+ Trade Receivables — Current	-1.6	-3.7	-1.1	-1.0
+ Trade Payables — Current	-1.0	0.2	1.9	-0.1
Cash from Operating Activities
Profit Before Tax (per I/S)	32.9	35.2	43.9	50.5
Cash from Operating Activities	17.1	8.1	27.9	26.5
Cash from Investing Activities
+ Disp of Fixed Assets	0.0	0.0	—	0.0
+ Purchase of Investments (Equity / Debt)	16.7	26.8	37.6	39.1
+ Dividends Received — Investing	0.0	0.1	0.1	0.2
Cash from Investing Activities	2.6	-0.6	-17.0	-19.5
Cash from Financing Activities
+ Payment of Lease Liabilities	0.5	0.5	0.6	0.6
Cash from Financing Activities	-21.0	-7.1	-7.6	-8.9
Net Changes in Cash	-1.4	0.5	3.2	-1.8
Reference Items
EBITDA	27.7	30.5	37.2	40.2
EBITDA Margin %	20.29	21.49	24.53	23.81
Free Cash Flow (CFO − Capex)	17.1	8.1	27.9	26.5
Cash Flow to Net Income	0.69	0.31	0.87	0.76

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.